A quantitative enzyme-linked immunosorbent assay was used to measure the concentration of fluid-phase complement C5b-9 complexes (SC5b-9) in the cerebrospinal fluid (CSF) of 14 patients with acute monophasic Guillain-Barre Syndrome (GBS), 21 patients with multiple sclerosis (MS), and 11 patients with noninflammatory central nervous system (CNS) diseases. SC5b-9 complexes were detected in the CSF of 13 of 14 patients with acute GBS (mean, 3.08 μg/ml; range, 0 to 7.1 μg/ml) and 16 of 21 patients with MS (mean, 1.83 μg/ml; range, 0 to 7.5 μg/ml). In the control group of patients with noninflammatory CNS diseases, SC5b-9 was not detected in eight of 11 and was present in low concentrations in the remaining three patients (mean, 0.28 μg/ml; range, 0 to 1.7 μg/ml). The finding of SC5b-9 complexes in the CSF of patients with GBS and MS suggests that terminal complement components may participate in the tissue-damaging processes in these diseases.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of Immunology|
|Publication status||Published - 1986|
ASJC Scopus subject areas